Randomized Clinical Trial Design to Assess Abatacept in Resistant Nephrotic Syndrome

Kidney International Reports

Ayanbola Elegbe¹  Michael Maldonado¹  Sandra Overfield¹  Cathie Spino²  Anna Greka³  John Sedor⁴  Lawrence Holzman⁵  Debbie S. Gipson⁶  Sharon Adler⁷  Michael Somers⁸  Howard Trachtman⁹  Jeffrey B. Kopp^1,10 

[1] Bristol-Myers Squibb, Princeton, New Jersey, USA;Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA;Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, and Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, USA;Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA;Department of Medicine, University of Pennsylvania Medical School, Philadelphia, Pennsylvania, USA;Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA;Division of Nephrology and Hypertension, Harbor-University of California Los Angeles Medical Center, Los Angeles, California, USA;Division of Nephrology, Boston Children’s Hospital, Boston, Massachusetts, USA;Division of Nephrology, Department of Pediatrics, New York University Langone Medical Center, New York, New York, USA;Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA;

关键词: albuminuria;    chronic kidney disease;    glomerular disease;    podocyte;    proteinuria;   

DOI  :  10.1016/j.ekir.2017.08.013

来源: DOAJ

【 授权许可】

Unknown